Galway, Ireland-based medical device firm Aerogen has completed a management buyout from its US parent, San Carlos, Calif-based Nektar Therapeutics for an undisclosed amount. Under the terms of the deal, Nektar will maintain a minority share in the business.
Aerogen’s core technology, the OnQ™ micropump aerosol generator, is currently used worldwide in nebulizers for drug delivery to patients in the intensive care and homecare settings. Aerogen’s products are available in more than 50 countries, including the United States, Japan, and Germany.
The company plans to announce new partnerships with a number of US and European market leaders in both the medical field and commercial products area in the near future.
